Your browser is no longer supported. Please, upgrade your browser.
DMAC DiaMedica Therapeutics Inc. daily Stock Chart
DiaMedica Therapeutics Inc.
Index- P/E- EPS (ttm)-0.80 Insider Own9.04% Shs Outstand13.11M Perf Week-2.91%
Market Cap65.99M Forward P/E- EPS next Y-1.40 Insider Trans- Shs Float12.86M Perf Month17.56%
Income-9.80M PEG- EPS next Q-0.14 Inst Own29.30% Short Float0.27% Perf Quarter6.86%
Sales- P/S- EPS this Y-20.00% Inst Trans101.75% Short Ratio0.62 Perf Half Y48.25%
Book/sh1.02 P/B4.58 EPS next Y- ROA-83.10% Target Price- Perf Year68.59%
Cash/sh0.89 P/C5.24 EPS next 5Y- ROE-92.80% 52W Range1.70 - 5.93 Perf YTD-3.71%
Dividend- P/FCF- EPS past 5Y13.60% ROI- 52W High-22.43% Beta2.29
Dividend %- Quick Ratio15.10 Sales past 5Y- Gross Margin- 52W Low170.59% ATR0.41
Employees8 Current Ratio15.10 Sales Q/Q- Oper. Margin- RSI (14)58.61 Volatility6.52% 11.11%
OptionableNo Debt/Eq0.00 EPS Q/Q32.00% Profit Margin- Rel Volume0.44 Prev Close4.67
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume55.82K Price4.60
Recom- SMA203.90% SMA5024.91% SMA20030.85% Volume7,441 Change-1.50%
Apr-30-19Initiated Dougherty & Company Buy $8
Mar-05-19Initiated Lake Street Buy $9
May-19-20 04:42PM  
May-13-20 04:41PM  
May-07-20 04:30PM  
Mar-26-20 09:12AM  
Mar-24-20 06:00AM  
Mar-23-20 04:35PM  
Mar-22-20 02:25PM  
Mar-17-20 08:10AM  
Mar-09-20 08:10AM  
Feb-13-20 04:35PM  
Feb-11-20 07:15AM  
Dec-23-19 02:32PM  
Dec-17-19 04:14PM  
Nov-13-19 04:12PM  
Nov-06-19 04:04PM  
Nov-05-19 04:04PM  
Oct-14-19 07:42AM  
Sep-06-19 09:00AM  
Sep-03-19 04:15PM  
Aug-13-19 04:35PM  
Aug-12-19 08:00AM  
Aug-08-19 04:00PM  
Jun-21-19 07:18AM  
Jun-20-19 07:25AM  
Jun-19-19 04:04PM  
May-21-19 08:34AM  
May-14-19 06:00AM  
May-13-19 04:48PM  
May-06-19 08:54AM  
Apr-30-19 04:58PM  
Mar-19-19 04:30PM  
Mar-18-19 01:56PM  
Mar-12-19 01:00PM  
Feb-14-19 08:00AM  
Jan-22-19 07:45AM  
Jan-16-19 04:00PM  
Jan-10-19 08:27AM  
Jan-09-19 05:00PM  
Jan-03-19 10:41AM  
Dec-02-18 05:01PM  
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company also develops DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. It has a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. to develop and commercialize DM199 for acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was founded in 2000 and is headquartered in Minneapolis, Minnesota.